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A B S T R A C T
The objectives of this study were to investigate: 1) the activity of pseudocholinesterase
(PChE) in patients with uterine cervical cancer in different stages (uterine cervical car-
cinoma in stages II b and III and recurrent cervical carcinoma in stages III and IV a,b)
and to compare it to the enzyme activity in patients with benign tumour of the uterus,
and 2) the effects of radiotherapy on enzyme activity in those patients with uterine cervi-
cal carcinoma for which the chosen treatment was radical radiotherapy. Thirty patients
with uterine cervical carcinoma in stages II b and III (Group A), sixteen patients with
recurrent cervical carcinoma in stages III and IV a,b (Group B) and thirty-eight pa-
tients with benign tumours of the uterus (control, Group C) were evaluated and their
PChE activity was determined prior to any treatment (pre-therapy enzyme activity). All
eighty-four patients were free of any liver disease. The results have shown that the pa-
tients of Group A had the pre-therapy PChE activity practically identical to those in
group C, but patients of Group B had significantly lower values of PChE with respect to
enzyme activities of Groups A and C (p< 0.001).That is to say, PChE activity was influ-
enced by the extent to which the malignancy had spread. Radical radiotherapy (up to 8
weeks in doses higher than 50 Gy into point A; average 80 Gy) which was the chosen
treatment only for patients from group A did not cause a significant inhibition of PChE
activity in any patients in comparison with their control values. With regard to the role
of PChE in hydrolysis of succinylcholine, our results about the influence of the malig-
nant disease and the radiotherapy on PChE activity are clinically significant.
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Introduction
Two types of cholinesterases have been
recognized in mammalian systems1,2. The
first is true cholinesterase (acetylcholi-
nesterase, AChE; Enzyme Commission
Number: EC 3.1.1.7), which is responsi-
ble for hydrolysis of acetylcholine at the
neuromuscular junction and is found in
the nervous system and in red blood
cells1–4.
The second is pseudocholinesterase
(plasma cholinesterase, PChE, ChE,
butyrylcholinesterase, BuChE; Enzyme
Commission Classification Number: EC
3.1.1.8.). This is a serum esterase classi-
fied on the basis of its preference for
butyrylcholine as a substrate rather than
for other esters of choline1,2,5,6. PChE, like
albumin, is synthesised in liver cells and
released into plasma immediately follow-
ing its synthesis7,8. The PChE concentra-
tion in plasma is therefore a reflection of
the rate of its formation in hepatocytes,
and any alteration of its activity can be
an indication of cellular impairment9,10.
The true physiological function of PChE
is still unknown. Consequently, it is con-
sidered to have an essential role in the
transmission of slow nerve conduction, or
in the regulation of plasma choline
levels1,2 or in serum lipid and lipoprotein
metabolism12–15. From the pharmacologi-
cal point of view, this enzyme is responsi-
ble for rapid hydrolysis and short dura-
tion of action of succinylcholine16,17 and
the ester type of local anaesthetics18. A
significant reduction in PChE activity
may prolong muscle relaxation during
surgery. For a practical reason it is of im-
portance to determine whether the reduc-
tion in PChE activity is inherited (rare
genetic variant of atypical or dibucaine-
-resistant enzyme) or acquired19,20. The
frequency of the acquired reduction in en-
zyme activity is significantly higher than
in the inherited reduction and it could be
a consequence of decreased enzyme syn-
thesis due to liver disease (i.e. acute hepa-
titis or hepatic metastasis)9,21,22 or ma-
lnutrition23, carcinoma24, uremia25, treat-
ment with glucocorticoids28,29, ranitidine30,
oral contraceptives with oestrogens31, etc.
Generally, there are very few data
about the influence of radiotherapy on
enzyme activity of AChE32 or PChE. The
results of some investigators show that
X-ray therapy in patients with maligno-
ma was followed or by a poor reduction of
PChE activity33, or that the influence of
X-ray therapy on PChE activity is di-
rectly related to signs of disease and en-
zyme activity observed prior to treat-
ment34.
With regard to the clinical importance
of PChE in anaesthesia, and the high in-
cidence of uterine cervical carcinoma as a
malignant disease, the aims of this study
were to determine plasma cholinesterase
activity in patients with uterine cervical
carcinoma in stages II b and III and pa-
tients with recurrent cervical carcinoma
in stages III and IV a,b and to compare
their values with the enzyme activities of
patients with benign tumour of the ute-
rus. Another aim of the study was also to
investigate the effect of radiotherapy on
PChE activity in patients with cervical
carcinoma for which this therapy was
treatment of choice.
Patients and method
Total number of patients included in
this study was 84 and they were divided
into three groups. Forty-six patients with
uterine cervical carcinoma in different
stages were in group A and B and 38 pa-
tients with benign tumours of uterus
were included in control, group C. No pa-
tients in Group A and C had a history of
carcinoma and no patients in all three
groups were treated with glucocorticoids,
oral contraceptives, oestrogens, barbitu-
rates and sympatolytic drugs for at least
1 month before the beginning of our in-
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vestigation. Pregnant women were also
excluded. The study started in January
1992 and was closed in April 1995. The
Ethics Committee of the School of Medi-
cine, University of Zagreb, Croatia ap-
proved the study.
Group A consisted of 30 patients with
uterine cervical cancer stages II b and III
(FIGO classification, 1988.) at initial di-
agnosis. Their performance status (ECOG)
was 0–1. The treatment for all of them
was the same, i.e. radical radiotherapy,
and most of them received radiation
treatment up to 8 weeks (average 6
weeks) in doses greater than 50 Gy (aver-
age 80 Gy) into point A.
Group B consisted of 16 women with
recurrent cervical cancer in stages III
and IV a,b of the disease (FIGO classifica-
tion 1988.) that received prior radiother-
apy (2–6 years before). Their performan-
ce status (ECOG) was 2–3. They were
free of metastatic liver disease, but most
of them had heavily impaired kidney
function. The treatment for all patients
from Group B was not the same (i.e. pal-
liative and/or symptomatic), and for this
reason, all patients from Group B were
excluded from further investigation.
Control, Group C consisted of patients
with benign tumour of the uterus and
who were treated only surgically.
PChE monitoring
In all patients from Group A blood
samples for the measurement of PChE
were taken once prior to the beginning of
radiotherapy (i.e. after admission to the
hospital), and twice a week during radio-
therapy. In all patients from Groups B
and C blood samples for measuring PChE
activity were taken only once after ad-
mission to the hospital.
Enzyme activities measured in all pa-
tients after admission to the hospital (i.e.
before any treatment for all three Groups)
represent their pre-therapy enzyme ac-
tivities.
Since the atypical or dibucaine-resis-
tant enzyme in European population is
very rare, we did not determine dibucaine
phenotype in our patients.
Measurement of PChE activity
Blood was centrifuged at 1400 g for 10
min and stored at –20 °C until analysed.
PChE activity was determined by the
method of Ellman et al. using butyryl-
thiocholine as substrate35. Enzyme activ-
ity is expressed as  mol of substrate hy-
drolyzed per min per ml of plasma. Under
standard conditions and using the Ell-
man reaction and butyrylthiocholine as
substrate, the range of values of enzyme
activities for normal healthy individuals
is 2.5–6.7 or 2.1–5.25  mol/min/ml36,37.
Statistical analysis
Data are shown as mean  standard
deviation of the mean.
Results were analysed using unpaired
and paired Student  s test, Friedman ana-
lysis of variance and Wilcoxon pairs test.




The enzyme activities measured in all
the patients from Groups A and B and
Group C after admission to the hospital,
i.e. before any treatment are presented in
Table 1. The average age of each Group
was as follows: Group A 51.6  12.7 years,
Group B 56.8  10.3 years and Group C
45.2  10.3 years.
The mean values of PChE activity in
patients from Group A and B were 4.36
 1.30 and 2.46 1.24  mol. min–1. ml –1 re-
spectively. A significant difference in the
enzyme activity existed between Group A
and Group B (p< 0.001); i.e. the patients
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from Group B had significantly 1.7 times
lower values of PChE activity in compari-
son with Group A. The same statistically
significant difference was noted between
the mean values of PChE activity of pa-
tients from Group B and control group C
(p< 0.001) (Table 1). But there was no sig-
nificant difference in the PChE activity
between Group A and the Group C.
Enzyme activity during radiotherapy
PChE activity in 30 patients from
Group A with uterine cervical cancer
stages II b and III during radiotherapy is
shown in Table 2.
The activity of PChE did not signifi-
cantly change in all 30 patients from
Group A, i.e. radical radiotherapy in
these patients with total radiation doses
higher than 50 Gy during 4–8 weeks ex-
erted no significant effect on PChE activ-
ity in comparison with their control val-
ues (p >0.05) (Table 2).
As shown in Table 2, the average du-
ration of radiotherapy in 80% of the pa-
tients was 6 weeks. That is the main rea-
son why the number of patients after that
time was less than 50%. So, although the
number of patients in the 7th and 8th week
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TABLE 1
PChE ACTIVITY IN PATIENTS BEFORE ANY TREATMENT
(PRE-THERAPY ENZYME ACTIVITY)
Values are expressed as mean  SD
Group Number ofPatients Age (yr.)
Activity of PChE
 mol. min–1.ml–1
A 30 51.6 12.7 4.36 1.30
B 16 56.8 10.3 2.46 1.24*
C (control) 38 45.2  10.3 4.46 1.19
* Indicates a statistically significant difference of the PChE value when compared
with the Group A and Group C (p < 0.001)
TABLE 2
PChE ACTIVITY IN PATIENTS OF GROUP A DURING
RADIOTHERAPY UP TO 8 WEEKS










1st 30 4.31 1.26
2nd 30 4.22 0.92
3rd 30 4.36 0.99
4th 30 4.44 0.99
5th 27 4.35 0.99
6th 24 4.90 0.99
7th 13 4.22 0.79
8th 5 3.92 1.30
of radiotherapy was 13 and 5 respecti-
vely, in comparison with the number at
the beginning of therapy, the drop in the
activity in the 8th week was only about
10%.
Discussion
This study has shown that all patients
had plasma cholinesterase activity within
the normal range before the beginning of
any therapy and that all patients with re-
current cancer (group B) had statistically
significant lower values than Groups A
and C. Our results have also shown that
radiotherapy in patients from Group A
did not affect the plasma cholinesterase
activity.
With regard to the range of values of
enzyme activity for normal healthy indi-
viduals that were mentioned earlier, it
can be seen that the PChE values of pa-
tients from Group A were near the upper
limit of enzyme activities for healthy per-
sons. On the other hand, mean value of
PChE activity in patients from Group B
(recurrent cervical cancer in stages III
and IV a, b) was on the lowest limit of
normal values. We suppose that signifi-
cant difference in PChE activity between
the patients of Groups A and B before the
any therapy was due to the poor general
condition and advanced malignant dis-
ease in all patients from Group B. On the
other hand, our results have shown a
similar direct relationship between the
PChE activity and the degree of malig-
nant disease, as it was found by other in-
vestigators. Thus, Kaniaris. et al. deter-
mined PChE levels in 180 patients with
carcinoma and in 146 normal subjects24.
Serum cholinesterase activity was signif-
icantly lower in patients with malignoma
than in normal controls, though still
within normal range. Kaniaris et al. also
concluded that the degree of serum PChE
activity inhibition was influenced both by
the extent to which the malignancy had
spread and by the site of the primary car-
cinoma. Low PChE activity was also
found in 118 of 2215 surgical patients38
and out of 118 patients, 23 (19.5%) had
malignancies (non-metastatic or meta-
static). Kreuscher H. et al. compared the
activity of PChE between normal pati-
ents and patients with malignant tumors
or biliary obstruction and found that due
to tumors or inflammation those patients
had a significant decrease of enzyme ac-
tivity39. All these examples clearly show
that the only reason for significantly lo-
wer PChE activity in our patients from
Group B is the advanced malignant dis-
ease. Other factors, like the time of blood
sampling, or intake of food and drink do
not seem to be important.
It is mentioned that in patients with a
significant reduction of PChE activity the
effect of succinylcholine may be prolon-
ged irrespective of their PChE phenotype
26,27,31. So, Viby-Mogensen and Hanel re-
ported an episode of prolonged apnoea af-
ter suxamethonium in 14 patients who
showed a low activity of the usual type of
enzyme40. According to their results, the
low PChE activity due to an acquired de-
ficiency, i.e. liver disease, chronic debili-
tating disease and carcinoma, was estab-
lished in 12 out of the 14 patients. In our
investigations, PChE activity in all 16 pa-
tients from Group B (recurrent cervical
cancer in stages III and IV a, b) after ad-
mission to the hospital and before any
therapy was also significantly lower in
comparison with subjects without mali-
gnoma (Control, Group C) or with ma-
lignoma in the early stage of disease
(Group A).+ Although we did not deter-
mine the phenotype of PChE, we sup-
posed that most patients from all groups
had the usual phenotype, because the fre-
quency of atypical phenotypes (i.e. atypi-
cal homozygotes and heterozygotes) in
the European population is practically
very low (< 5%)41. For this reason we con-
sider that hydrolysis of succinylcholine in
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patients with uterine cervical cancer in
advanced stages of the disease and with
the low acquired PChE activity due to
malignancy may be prolonged as well.
These facts about the influence of ad-
vanced stages of the malignant disease
on PChE activity are important for the
anaesthesiologist in case a planned or
emergency surgery in these patients is
required.
Our results have shown that radio-
therapy up to 8 weeks in patients from
Group A did not significantly decrease
the PChE activity and it was practically
similar to the control value all the time.
The results of mean enzyme activity mea-
surement in 27–30 patients from Group A
during the 4–6 weeks of radiotherapy
show that the decrease in PChE activity
was approximately 5% compared with
their control value. Also, a decrease of
PChE activity in 5 patients from Group A
who were on radiotherapy during 8 weeks
was between 0–10% (Table 2). Conse-
quently, any relationship between the
PChE activity and the dose and duration
of radiotherapy does not exist. It is
known that the half-life of PChE in pla-
sma is in the 8–12 days range2. In our re-
sults, values of the PChE activity during
radiotherapy were practically unchanged
and it is not probable that the radiother-
apy in patients with early stage of dis-
ease had any effect on the enzyme syn-
thesis in the liver or on its activity in
plasma.
Our results are similar to those ob-
tained by Guminska et al34. where the ac-
tivity of PChE was measured in 21 pa-
tients with Hodgkin’s disease in different
stages. These results have shown that
the least changes in enzyme activity in
the course of X-ray therapy were obser-
ved in the group of patients who had the
least-advanced signs of disease. These
changes in PChE activity were not signif-
icant. But the patients with the greatest
progress of the disease had a decrease in
cholinesterase activity observed prior to
treatment and which intensified during
X-ray therapy. The possible reasons are
probably the poor general condition of pa-
tients and/or the radiotherapy.
In conclusion, patients with early sta-
ge of uterine cervical carcinoma have the
same values of PChE activity as patients
with benign tumour of the uterus, while
patients with uterine cervical carcinoma
in advanced stage have significantly very
low values of enzyme activity in compari-
son with patients in the early stage of the
disease, or control group. In patients with
the early stage of malignant disease (ute-
rine cervical carcinoma in stage II b and
III) treatment with radiotherapy did not
significantly affect the activity of PChE.
Since the pseudocholinestrase is of clini-
cal importance in hydrolysis of succinyl-
choline, these results also have clinical
significance for the anaesthesiologist.
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AKTIVNOST KOLINESTERAZE U PLAZMI BOLESNICA TIJEKOM
RADIOTERAPIJE RAKA VRATA MATERNICE
S A @ E T A K
Ciljevi ovog istra`ivanja bili su: 1) u pacijentica s rakom vrata maternice u razli-
~itim stadijima maligne bolesti utvrditi aktivnost pseudokolinesteraze (PChE) i uspo-
rediti s aktivnosti istog enzima u pacijentica oboljelih od benignog tumora maternice;
2) u pacijentica s rakom vrata maternice u kojih radioterapija predstavlja izbor lije-
~enja ispitati u~inke radioaktivnog zra~enja na aktivnost PChE. Istra`ivanje je pro-
vedeno na 30 pacijentica s rakom vrata maternice II b i III stadija bolesti (Grupa A), na
16 pacijentica s rekurentnom malignom bolesti III i IV a,b stadija (Grupa B) te na 38
pacijentica s benignim tumorom maternice (kontrola, grupa C). Niti u jedne pacijentice
nije dokazano o{te}enje funkcije jetre. U svih 84 pacijentica aktivnost PChE prvi puta
izmjerena je neposredno nakon primitka na lije~enje (aktivnost enzima prije po~etka
bilo kakve terapije). Rezultati mjerenja pokazali su da je aktivnost PChE u pacijentica
iz grupe A prakti~ki identi~na aktivnosti enzima pacijentica iz Grupe C, dok su pa-
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cijentice iz grupe B (rekurentna maligna bolest) imale zna~ajno ni`e kontrolne vrije-
dnosti enzima i u odnosu na one iz Grupe A i u odnosu na pacijentice iz skupine C (p<
0,001).O~ito je da pro{irenost malignog procesa utje~e na aktivnost enzima. Postupak
radioterapije (duljina terapije do 8 tjedana, doze ve}e od 50 Gy u to~ku A; prosje~no
80Gy) odabran je samo za pacijentice Grupe A. Rezultati mjerenja aktivnosti PChE
tijekom postupka radioterapije pokazali su da niti u jedne pacijentice iz grupe A nije
do{lo do zna~ajnog pada aktivnosti PChE u usporedbi s njihovim kontrolnim vrijedno-
stima. Obzirom na ulogu koju pseudokolinesteraza ima pri razgradnji sukcinilkolina,
na{i rezultati o utjecaju maligne bolesti i radioterapije na aktivnost enzima imaju kli-
ni~ku va`nost.
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